(+)-N,N-diethyl-N'-<(3R,4aS,10aS)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzoquinolinyl>sulfamide | 140630-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (+)-N,N-diethyl-N'-<(3R,4aS,10aS)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzoquinolinyl>sulfamide
• 英文别名: Quinagolidum；(3R,4aR,10aS)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
• CAS: 140630-79-1
• 化学式: C₂₀H₃₃N₃O₃S
• 分子量: 395.566
• InChiKey: GDFGTRDCCWFXTG-SCTDSRPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  81.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (+/-)-(3α,4aα,10aβ)-3-(tertbutoxycarbonyl)-1,2,3,4,4a,5,10,10a-octahydro-1,6-dimethoxybenzo(g)quinoline 在 盐酸 、 palladium on activated charcoal 、 氢气 、 三溴化硼 、 一水合肼 、 溶剂黄146 、 亚硝酰氯 、 三乙胺 、 三氟乙酸 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 丙醇 、 乙醚 、 氯仿 、 水 为溶剂， 反应 0.75h， 生成 (+)-N,N-diethyl-N'-<(3R,4aS,10aS)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzoquinolinyl>sulfamide
  参考文献：
  名称：

  Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3.alpha.,4a.alpha.,10a.beta.)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide

  摘要：

  The synthesis and preliminary pharmacological evaluation of the optical antipodes of the title compound (+/-)-1 (CV 205-502) is presented. The dopaminomimetic activity is shown to reside entirely in the (-) enantiomer. Crystallographic analysis has proven that the absolute configuration of the active (-) enantiomer corresponds to that of its ergoline analogue 3 (CQ 32-084) and of apomorphine (5).

  DOI：

  10.1021/jm00148a030

文献信息

• Use of quinoline derivatives in treating cancer
  申请人：SANDOZ AG

  公开号：EP0373658A2

  公开（公告）日：1990-06-20

  Low molecular weight quinoline derivatives, in free form or in pharmaceutically acceptable salt form are useful in reducing the spread or growth of secondary cancer cells associated with treatment of a primar cancer tumor, e.g. perioperative treatment of primary operable cancer tumors, and in treating meningiomas.

  游离形式或药学上可接受的盐形式的低分子量喹啉衍生物可用于减少与原发性癌症肿瘤治疗相关的继发性癌细胞的扩散或生长，例如原发性可手术癌症肿瘤的围手术期治疗，以及脑膜瘤的治疗。
• DOSAGE FORMS AND METHOD FOR AMELIORATING MALE ERECTILE DYSFUNCTION
  申请人：——

  公开号：US20010018069A1

  公开（公告）日：2001-08-30

  The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.

  一种用于口服的药物组合物，包括载体和选自多巴胺激动剂、睾酮及其混合物的活性成分，该组合物为快速分散剂型，旨在口腔中快速释放活性成分，用于制造治疗男性勃起功能障碍的药物。
• Oral fast-dissolving compositions for dopamine agonists
  申请人：——

  公开号：US20020156056A1

  公开（公告）日：2002-10-24

  The present invention discloses the use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.

  本发明公开了一种口服药物组合物的用途，该组合物由载体和选自多巴胺激动剂、睾酮及其混合物的活性成分组成，该组合物为快速分散剂型，旨在口腔中快速释放活性成分，用于制造治疗男性勃起功能障碍的药物。
• Dopamine-agonist combination therapy for improving sleep quality
  申请人：Barberich J. Timothy

  公开号：US20050267176A1

  公开（公告）日：2005-12-01

  The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone.

  本发明一般涉及由多巴胺激动剂和镇静剂组成的药物组合物。在一个优选的实施方案中，多巴胺激动剂是光学纯的(S)-双甲基西布曲明。在一个优选的实施方案中，镇静剂是光学纯（S）-佐匹克隆或光学纯（S）-N-去甲基佐匹克隆。在一个优选的实施方案中，多巴胺激动剂是光学纯的(S)-双甲基西布曲明；镇静剂是光学纯的(S)-佐匹克隆或光学纯的(S)-N-去甲基佐匹克隆。本发明的药物组合物可用于治疗不安腿综合征和周期性肢体运动障碍以及各种睡眠障碍。此外，本发明还涉及一种治疗不宁腿综合征、周期性肢体运动障碍、睡眠异常或失眠症患者的方法，包括联合给药治疗有效量的多巴胺激动剂和治疗有效量的镇静剂。在一个优选的实施方案中，多巴胺激动剂是光学纯的(S)-双甲基西布曲明。在一个优选的实施方案中，镇静剂是光学纯的(S)-佐匹克隆或光学纯的(S)-N-去甲基佐匹克隆。在一个优选的实施方案中，多巴胺激动剂是光学纯的(S)-双甲基西布曲明；镇静剂是光学纯的(S)-佐匹克隆或光学纯的(S)-N-去甲基佐匹克隆。
• ORAL FAST-DISSOLVING COMPOSITIONS FOR DOPAMINE AGONISTS
  申请人：R.P. Scherer Technologies, Inc.

  公开号：EP0850050B1

  公开（公告）日：2000-09-13